blinatumomab,inotuzumab
astellas pharmaceuticals,amgen,ucb,pfizer
['leusm', 'blinatumomab', 'inotuzumab']
congress #eha22 | presented data supporting hyper-cvad with sequential blinatumomab +/- inotuzumab ozogamicin in pts &gt;60 yrs with nd ph-ve b-all. n=58. overall mrd negativity rate=95%, cr=100%. 3 yr cr &amp; os rates=84% &amp; 85%. #allsm #leusm 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm